Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial

Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.